Published in Blood Weekly, November 24th, 2005
Verax will use the funds to complete development and begin commercialization of its first product, the Platelet PGD test, a rapid test for specific detection of bacterial contamination of platelets immediately prior to transfusion.
KB Partners led the series B financing and was joined by new investors CNF Investments, SightLine Partners, Teknoinvest, and Long River Ventures as well as existing investor BioVentures Investors. Adams Harkness acted as the exclusive placement agent and financial advisor to Verax.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.